Ikke godt å si aksjethj, men nå har det gått ca 25000 til kr ca 29,0, og kursen har vært nede på 28 tallet. Verd å merke seg at volumet så langt i dag (kl 12.30) allerede er større enn det har vært på en hel dag siden de første par dagene etter at emisjonen ble meldt.
ja den er god men,
REK: exstensionstudiet: Ettersom det er en ekstra behandling vil det også bli lagt til en ekstra radiologisk undersøkelse til slutt for å evaluere sydommen.
1 Like
Den er god, her smører man seg med tålmodighet. Dessverre har man ikke mer å kjøpe for.
Ble det for mye Møllers tran? Gantistene må trå skikkelig til dersom antallet ubenyttede retter er betydelig. Det kan det da ikke være; enhver rasjonell aktør vil jo selge de rettighetene som ikke bli benyttet. Er selgerne folk som har ganske enkelt har forandret mening om hvor store midler de vil binde opp i Pcib-aksjen.? Jeg tror det er store aktører som foretar loftsrydding.
PCI Biotech: Final results of the rights issue
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, HONG KONG OR SOUTH AFRICA, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.
Oslo, Norway, 04 October 2018. Reference is made to the previous announcements by PCI Biotech Holding ASA (“PCI Biotech” or the “Company”) in respect of the fully underwritten rights issue of 12,000,000 new shares (.Offer Shares.) in the Company (the “Rights Issue”). The subscription period in the Rights Issue expired at 16:30 CET, 03 October 2018.
At the expiry of the subscription period the Company had received subscriptions for a total of 10,424,108 new shares. In total 12,000,000 new shares were offered, thus the Rights Issue was subscribed with approximately 87 per cent of the shares offered. Approximately 77 per cent of the new shares on offer (approximately 9.2 million shares) were subscribed through the exercise of subscription rights. Approximately 10% per cent of the new shares on offer (approximately 1.2 million shares) were subscribed for through oversubscription and subscription without shares.
In a board meeting today, the Board of Directors of PCI Biotech approved the final allocation of the shares offered in the Rights Issue based on the allocation criteria set out in the prospectus dated 17 September 2018. A total of 12,000,000 new shares have been allocated. Approximately 9.2 million new shares have been allocated to subscribers on the basis of exercised subscription rights. Approximately 0.9 million new shares have been allocated to holders of subscription rights as a result of oversubscription. Approximately 0.3 million new shares have been allocated to subscribers without subscription rights. Approximately 1.6 million new shares have been allocated to the underwriters in accordance with the underwriting commitments of the respective underwriters to the extent the underwriters have not fulfilled such commitments by subscribing for offer shares in the subscription period.
Notifications of allocated new shares and the corresponding subscription amount to be paid by each subscriber are expected to be distributed today. Payment for the allocated shares falls due on 08 October 2018 in accordance with the payment procedures described in the prospectus.
The new shares may not be transferred or traded before they have been fully paid and the share capital increase pertaining to the Rights Issue has been registered with the Norwegian register of Business Enterprises. It is expected that the share capital increase will be registered in the Norwegian Register of Business Enterprises on or about 09 October 2018 and that the new shares will be admitted to trading on the Oslo Stock Exchange on or about 10 October 2018.
Timeline
Allocation of new shares and distribution of allocation letters 04 October 2018
Payment for new shares 08 October 2018
Capital increase registered on or about 09 October 2018
Listing of new shares on or about 10 October 2018Through the Rights Issue, PCI Biotech will receive gross proceeds in the amount of NOK 360 million. The Company’s extraordinary general meeting held on 14 September 2018, resolved to increase the share capital of the company with NOK 36,000,000 through the issue of 12,000,000 new shares as a result of the rights issue. Following registration of the share capital increase pertaining to the Rights Issue in the Norwegian Register of Business Enterprises, the Company’s share capital will be NOK 110,984,670 divided by 36,994,890 shares, each with a nominal value of NOK 3.00.
“We are pleased with the continued support of our shareholders and the interest from external investors in the Rights Issue. The capital increase of NOK 360 million enables us to perform the fima_Chem_ pivotal study, as well as further develop our pipeline and PCI Biotech as a company”, says Per Walday, CEO, PCI Biotech.
Contact information:
Ronny Skuggedal, CFO, [email protected], Mobile: +47 9400 5757
For more information visit: www.pcibiotech.com
Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, Oslo, NO-0379 NorwayImportant Notice
The contents of this announcement have been prepared by, and are the sole responsibility of, the Company. The Company’s financial advisors are acting exclusively for the Company and no one else, and will not be responsible to anyone other than the Company for providing the protections afforded to their respective clients, or for advice in relation to the Rights Issue, the contents of this announcement or any of the matters referred to herein.The information in this announcement is for information purposes only and does not purport to be accurate or complete. No reliance may be placed for any purpose on the information contained in this announcement or its accuracy or completeness.
Matters discussed in this announcement may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as “believe”, “expect”, “anticipate”, “strategy”, “intends”, “estimate”, “will”, “may”, “continue”, “should” and similar expressions. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond its control. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. The information, opinions and forward-looking statements contained in this announcement speak only as at its date, and are subject to change without notice. Neither the publication and/or delivery of this announcement shall under any circumstances imply that there has been no change in the affairs of the Company or that the information contained herein is correct as of any date subsequent to the earlier of the date hereof and any earlier specified date with respect to such information.
A prospectus approved by the competent authority in Norway has been published by the Company and can be obtained on the Company’s website, subject to regulatory restrictions. Investors should not subscribe for any securities referred to in this announcement except on the basis of information contained in the prospectus.
Restrictions
Neither this announcement nor any copy of it may be made or transmitted directly or indirectly into the United States, Australia, Canada, Japan, Hong Kong or South Africa or any other jurisdiction where to do so would be unlawful. The Rights Issue (if made) and the distribution of this announcement and other information in connection with the Rights Issue may be restricted by law in certain jurisdictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws. Persons into whose possession this announcement or other information should come are required to inform themselves about and observe any such restrictions. The Company assumes no responsibility in the event there is a violation by any person of such restrictions.This announcement does not in itself constitute, and should not be construed as, an offer for sale or subscription of or solicitation or invitation of any offer to subscribe for or purchase any securities of the Company or its affiliates in any jurisdiction. The Rights Issue will not be made in any jurisdiction or in any circumstances in which such offer or solicitation would be unlawful. No steps have been taken or will be taken relating to the Rights Issue in any jurisdiction outside of Norway in which such steps would be required.
The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or any securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with applicable state law. There will be no public offer of the securities in the United States.
This announcement is only being distributed to and is only directed at persons in the United Kingdom that are (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”) or (ii) high net worth entities, and other persons to whom this announcement may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”). This announcement must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this announcement relates is available only to relevant persons and will be engaged in only with relevant persons. Persons distributing this announcement must satisfy themselves that it is lawful to do so.
Further information regarding restrictions applicable for the Rights Issue will be set out in the prospectus prepared for the Rights Issue.
About PCI Biotech
PCI Biotech is a biopharmaceutical company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms: fimaCHEM (enhancement of chemotherapeutics for localised treatment of cancer), fimaVACC (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery).Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The Company’s lead fimaCHEM programme consists of a clinical Phase I/II clinical study in bile duct cancer, an orphan indication with a high unmet need and without approved products. fimaVACC applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fimaNAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Forward-looking statements
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Nyheten er levert av GlobeNewswire.
http://www.netfonds.no/quotes/release.php?id=20181004.GlobeNewswire.GNW1000101443-en
Jeg tror det kommer en dump nå når garantistene får beskjed om hvor mye de må plukke opp. Og potensielt en ny dump når tilretteleggerne tvangsselger aksjene til de som ikke har skjønt at tegningen er bindende og lot være å ha penger på kontoen.
Så får vi se hva nyhetsstrømmen bringer etter det.
Dette blir fort grisete uten news.
hvorfor skal garantistene dumpe noe som helst, de får aksjen grisebillig
1,6mill aksjer fordelt på garantistgjengen er ikke mye
4 Likes
in this case Nyenburgh should end up with minimum 440,000 shares out of the 1,6 million left since they guaranteed 27,5% of the rights issue
7 Likes
Stiller meg bak JAXI, nå må jo Nyeburg ut i markedet å handle aksjer.
3 Likes
Enig. Kan godt være de fikk mindre enn de hadde håpet på også. De har jo jobbet kursen nedover for å få folk til å la være å bruke t-rettene.
Jeg sover uansett godt de neste ukene, uansett hvilken vei kursen går. Skal ikke selge en eneste aksje før studiet er ferdig. Holder kursen seg lavt uten dårlige nyheter, så ser jeg det som en glimrende kjøpsmulighet etterhvert som en får penger inn på konto som man kan investere.
3 Likes
Jeg hadde ikke fått med meg siste melding med resultatet fra tildelingen. Jeg tror 1.,6 millioner aksjer er 1,6 millioner mer enn de hadde regnet med. Noen av dem ønsker nok flere aksjer, men jeg tror også at noen av dem ikke ville ha det. Det disse som nå selger og skaper press på prisen tror jeg uten å spekulere i hvem som gjør hva.
Nå må dere slutte.
Det er ingenting som tilsier at Nyenburgh har gjort noe som helst. De gikk inn og lånte penger til PCIB og fikk 3.5% for det. Men nå ser det ut som de går i 0.
1 Like
Lets put this behind us…now. Money is (or will be) in the account. Piv stage 2 on the way, plus other potential good news flows over the next few months. Obviously not happy about dropping 45% over the last month, but from a company perspective this emisjon has been a success…just not from my bank account’s perspective.
3 Likes
Jeg tror nok det er flere som har valgt å droppe å bruke rettene etter at de så hvilken vei kursen gikk etter at rettene ble tatt av notering på mandag. Jeg var selv veldig usikker i går ettermiddag, men valgte å tegne. I dag angrer jeg siden jeg kunne kjøpt de til ca 29 nå.
Har plukket noen på 28 tallet nå og håper å kunne selge de over 30 en dag. Sikkert ikke den eneste som tenker i den retningen nå, men tydeligvis ikke mange nok til å motstå salgspresset.
1 Like
Å ha tålmodighet er nok en god strategi. Ei heller aldri dumt å ha litt i bakhånd til de store kjøpsanledningene. Men tipper at du prosentuelt vil ha en svært attraktiv avkastning på investeringen uavhengig av om g.a.v. er 45,- eller 29,- når interim leses av.
2 Likes
Går dette veien slik vi alle håper på, så spiller det til slutt liten rolle om man fikk aksjene til 29, 30, 35 eller 40 kroner. Da blir det sett på som en billig inngang uansett.
Skulle det ikke gå veien for PCIB, spiller det også liten rolle om man fikk aksjene for 29, 30, 35 eller 40 kroner. Da er det meste tapt.
Velkommen til Biotek.
4 Likes
Eneste naturlige å gjøre nå er å kjøpe hvis man kan. Jeg har tatt en post i dag, for første gang siden i fjor.
2 Likes
Vi får håpe du har rett i det Gautosaur! 
Geiran, Nyenburgh garanterte for 99 000 000 kroner, hva tror du de tenkte da de gjorde det?
At de skulle tjene 3,5 millioner kroner?
9 Likes